Genzyme patent expiration
1. Cerezyme patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5549892 | GENZYME | Enhanced in vivo uptake of glucocerebrosidase |
Aug, 2013
(10 years ago) | |
Drugs and Companies using IMIGLUCERASE ingredient
Market Authorisation Date: 23 May, 1994
Treatment: Method of treating a human subject having gaucher's disease
Dosage: INJECTABLE
More Information on Dosage
CEREZYME family patents
2. Clolar patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5661136 | GENZYME | 2-halo-2'-fluoro ARA adenosines as antinoplastic agents |
Jan, 2018
(6 years ago) | |
|
US5661136 (Pediatric) | GENZYME | 2-halo-2'-fluoro ARA adenosines as antinoplastic agents |
Jul, 2018
(6 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Dec 28, 2011 |
| Pediatric Exclusivity(PED) | Jun 28, 2012 |
Drugs and Companies using CLOFARABINE ingredient
Market Authorisation Date: 28 December, 2004
Treatment: Clolar is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens
Dosage: SOLUTION
How can I launch a generic of CLOLAR before it's drug patent expiration?
More Information on Dosage
CLOLAR family patents
3. Mozobil patent
expiration
MOZOBIL's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE42152 | GENZYME | Aromatic-linked polyamine macrocyclic compounds with anti-HIV activity |
Dec, 2018
(5 years ago) | |
| US6987102 | GENZYME | Methods to mobilize progenitor/stem cells |
Jul, 2023
(1 year, 6 days ago) | |
| US7897590 | GENZYME | Methods to mobilize progenitor/stem cells |
Jul, 2023
(1 year, 6 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 15, 2013 |
| Orphan Drug Exclusivity(ODE) | Dec 15, 2015 |
Drugs and Companies using PLERIXAFOR ingredient
NCE-1 date: 15 December, 2012
Market Authorisation Date: 15 December, 2008
Treatment: Use in combination with granulocyte-colony stimulating factor (g-csf) to mobilize hematopoietic stem cells to peripheral blood for collection & subsequent autologous transplantation in patients with n...
Dosage: SOLUTION
How can I launch a generic of MOZOBIL before it's drug patent expiration?
More Information on Dosage
MOZOBIL family patents
4. Renagel patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6509013 | GENZYME | Method of making phosphate-binding polymers for oral administration |
Aug, 2013
(10 years ago) | |
| US5496545 | GENZYME | Phosphate-binding polymers for oral administration |
Aug, 2013
(10 years ago) | |
| US7459151 | GENZYME | Phosphate-binding polymers for oral administration |
Aug, 2013
(10 years ago) | |
| US7014846 | GENZYME | Phosphate-binding polymers for oral administration |
Aug, 2013
(10 years ago) | |
| US5667775 | GENZYME | Phosphate-binding polymers for oral administration |
Sep, 2014
(9 years ago) | |
| US6733780 | GENZYME | Direct compression polymer tablet core |
Oct, 2020
(3 years ago) | |
Drugs and Companies using SEVELAMER HYDROCHLORIDE ingredient
Market Authorisation Date: 12 July, 2000
Treatment: Phosphate binding
Dosage: TABLET; CAPSULE
How can I launch a generic of RENAGEL before it's drug patent expiration?
More Information on Dosage
RENAGEL family patents
5. Renvela patent expiration
RENVELA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7014846 | GENZYME | Phosphate-binding polymers for oral administration |
Aug, 2013
(10 years ago) | |
| US5496545 | GENZYME | Phosphate-binding polymers for oral administration |
Aug, 2013
(10 years ago) | |
| US7459151 | GENZYME | Phosphate-binding polymers for oral administration |
Aug, 2013
(10 years ago) | |
| US6858203 | GENZYME | Method of making phosphate-binding polymers for oral administration |
Aug, 2013
(10 years ago) | |
| US6509013 | GENZYME | Method of making phosphate-binding polymers for oral administration |
Aug, 2013
(10 years ago) | |
| US5667775 | GENZYME | Phosphate-binding polymers for oral administration |
Sep, 2014
(9 years ago) | |
| US9095509 | GENZYME | Sachet formulation for amine polymers |
Dec, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Aug 12, 2012 |
| New Patient Population(NPP) | Nov 25, 2019 |
Drugs and Companies using SEVELAMER CARBONATE ingredient
Market Authorisation Date: 18 February, 2009
Treatment: Phosphate binding
Dosage: FOR SUSPENSION
How can I launch a generic of RENVELA before it's drug patent expiration?
More Information on Dosage
RENVELA family patents
6. Thyrogen patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5840566 | GENZYME | Isolation of a gene encoding human thyrotropin beta subunit |
Nov, 2015
(8 years ago) | |
| US6365127 | GENZYME | Isolation of a gene encoding human thyrotropin beta subunit |
Nov, 2015
(8 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Dec 14, 2014 |
Drugs and Companies using THYROTROPIN ALFA ingredient
Market Authorisation Date: 30 November, 1998
Treatment: Use as adjunct diagnostic for serum thyroglobulin (tg) testing
Dosage: INJECTABLE
More Information on Dosage
THYROGEN family patents